» Articles » PMID: 2212648

Augmentation of Monocyte Chemotaxis by 1 Alpha,25-dihydroxyvitamin D3. Stimulation of Defective Migration of AIDS Patients

Overview
Journal J Immunol
Date 1990 Oct 15
PMID 2212648
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Preincubation for 20 h with 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) markedly augmented the chemotactic responsiveness of human blood monocytes to the classical chemoattractant, FMLP. A modest enhancement of monocyte spontaneous locomotion in the absence of chemoattractants was also observed. Maximal increase of monocyte migration was observed after pretreatment with 10(-9) M 1,25(OH)2D3 and was detectable at FMLP concentrations ranging from 10(-10) to 10(-7) M. Pretreatment with 1,25(OH)2D3 augmented the number of monocyte high affinity FMLP receptors (1500 +/- 220 and 3800 +/- 300 sites per cell for untreated and 1,25(OH)2D3-pretreated cells, respectively) with no significant changes in Kd values (2 +/- 0.5 nM and 4 +/- 1 nM, for untreated and 1,25(OH)2D3-pretreated monocytes). Enhanced chemotaxis was not restricted to FMLP, because 1,25(OH)2D3-treated monocytes showed enhanced migration also in response to activated C components and chemotactic cytokines. In agreement with previous observations, monocytes from AIDS patients showed defective migration capacity. In vitro exposure to 1,25(OH)2D3 stimulated monocyte migration in all 10 patients examined with considerable quantitative differences among individuals. Regulating the responsiveness of mature monocytes to chemo-attractants, 1,25(OH)2D3, produced systemically or in situ by immunocompetent cells, could play a role in the regulation of the recruitment of monocytes at sites of inflammation, cell-mediated immunity, or bone resorption. The potential of 1,25(OH)2D3 as a restorative agent under conditions of defective phagocyte recruitment deserves further exploration.

Citing Articles

Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells.

Ghahramanipour Z, Naseri B, Mardi A, Sohrabi S, Masoumi J, Baghbani E Immunol Res. 2024; 73(1):6.

PMID: 39661295 DOI: 10.1007/s12026-024-09579-1.


Vitamin D status and its influence on outcomes following major burn injury and critical illness.

Al-Tarrah K, Hewison M, Moiemen N, Lord J Burns Trauma. 2018; 6:11.

PMID: 29721511 PMC: 5910591. DOI: 10.1186/s41038-018-0113-4.


Vitamin D in Human Immunodeficiency Virus Infection: Influence on Immunity and Disease.

Jimenez-Sousa M, Martinez I, Medrano L, Fernandez-Rodriguez A, Resino S Front Immunol. 2018; 9:458.

PMID: 29593721 PMC: 5857570. DOI: 10.3389/fimmu.2018.00458.


High-dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial.

Stallings V, Schall J, Hediger M, Zemel B, Tuluc F, Dougherty K Pediatr Infect Dis J. 2014; 34(2):e32-40.

PMID: 24988118 PMC: 4281504. DOI: 10.1097/INF.0000000000000483.


Treatment of an intramammary bacterial infection with 25-hydroxyvitamin D(3).

Lippolis J, Reinhardt T, Sacco R, Nonnecke B, Nelson C PLoS One. 2011; 6(10):e25479.

PMID: 21991312 PMC: 3184989. DOI: 10.1371/journal.pone.0025479.